接受基于利妥昔单抗治疗的非恶性免疫介导血液系统疾病患者中性粒细胞减少症的发生率及病程 - Suppr | 超能文献

相似文献

1

Incidence and time course of neutropenia in patients treated with rituximab-based therapy for non-malignant immune-mediated hematologic diseases.接受基于利妥昔单抗治疗的非恶性免疫介导血液系统疾病患者中性粒细胞减少症的发生率及病程

Am J Hematol. 2020 May;95(5):E117-E120. doi: 10.1002/ajh.25751. Epub 2020 Feb 17.

2

Dysfunctional Immune System Reconstitution After Rituximab Exposure In Utero.子宫内接触利妥昔单抗后免疫系统重建功能障碍。

J Pediatr Hematol Oncol. 2021 May 1;43(4):e601-e604. doi: 10.1097/MPH.0000000000001871.

3

Fulminant hepatitis B as a result of reactivation in hematologic patient after rituximab therapy.利妥昔单抗治疗后血液系统疾病患者因病毒再激活导致的暴发性乙型肝炎。

J Med Virol. 2016 Aug;88(8):1289-90. doi: 10.1002/jmv.24476. Epub 2016 Jan 20.

4

Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma.含利妥昔单抗方案治疗非霍奇金淋巴瘤后的迟发性中性粒细胞减少症

Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):761-5. doi: 10.1016/j.clml.2015.07.635. Epub 2015 Aug 6.

5

Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.接受聚乙二醇化脂质体阿霉素和利妥昔单抗免疫化疗的非霍奇金淋巴瘤患者间质性肺炎的发病率。

Ann Hematol. 2018 Jan;97(1):141-147. doi: 10.1007/s00277-017-3160-1. Epub 2017 Oct 31.

6

Hypersensitivity reactions to rituximab: 53 successful desensitizations in 7 patients with severe, near-fatal reactions.利妥昔单抗超敏反应：7例严重、近乎致命反应患者中的53次成功脱敏。

J Allergy Clin Immunol Pract. 2016 Sep-Oct;4(5):1000-2. doi: 10.1016/j.jaip.2016.05.013. Epub 2016 Jun 18.

7

Kaposi sarcoma associated with rituximab-based cytotoxic therapy.与基于利妥昔单抗的细胞毒性疗法相关的卡波西肉瘤

J Oncol Pharm Pract. 2020 Jan;26(1):220-223. doi: 10.1177/1078155219835592. Epub 2019 Mar 9.

8

Rituximab-associated colitis.利妥昔单抗相关的结肠炎。

Gastroenterol Hepatol. 2019 Apr;42(4):251-252. doi: 10.1016/j.gastrohep.2018.05.003. Epub 2018 Jun 5.

9

Rituximab-induced vasculitis: Does the immune complex of rituximab play a key role in developing paradoxical adverse events?利妥昔单抗诱导的血管炎：利妥昔单抗的免疫复合物在引发矛盾性不良事件中起关键作用吗？

J Dermatol. 2019 Sep;46(9):e311-e312. doi: 10.1111/1346-8138.14872. Epub 2019 Apr 10.

10

Rapid rituximab infusion is safe in paediatric and young adult patients with non-malignant indications.对于患有非恶性疾病指征的儿科和年轻成人患者，快速输注利妥昔单抗是安全的。

Br J Haematol. 2016 May;173(3):480-1. doi: 10.1111/bjh.13604. Epub 2015 Jul 24.

引用本文的文献

1

Late-Onset Neutropenia Induced by Rituximab in Rheumatic Diseases: A Report of Two Cases of Severe Presentation and a Literature Review.利妥昔单抗诱发的风湿性疾病迟发性中性粒细胞减少症：两例严重病例报告及文献综述

Cureus. 2025 Mar 5;17(3):e80074. doi: 10.7759/cureus.80074. eCollection 2025 Mar.

2

Late-onset Neutropenia after Rituximab Treatment for MPO-ANCA-associated Vasculitis.利妥昔单抗治疗MPO-ANCA相关性血管炎后迟发性中性粒细胞减少症

Intern Med. 2025 Feb 15;64(4):581-584. doi: 10.2169/internalmedicine.3357-23. Epub 2024 Jul 18.

3

Hypogammaglobulinemia, late-onset neutropenia, and infections following rituximab.